Participation Is Not Reform: Why 340B Discounts Should Follow the Patient
JCO Oncology Practice · 06.07.2026
DOI: 10.1200/op-26-00620 ↗Kurz gefasst
Leserbrief in der Zeitschrift JCO Oncology Practice, online erschienen am 06.07.2026. Verfasst von Ted Okon und 1 weiteren Autor:innen. Beteiligte Einrichtung: Ted Okon, MBA, and Nicolas Ferreyros, BA, Community Oncology Alliance, Washington, DC. Die Arbeit nennt 9 Literaturangaben.
Abstract (Originalsprache)
The 340B Drug Pricing Program is under growing scrutiny, and maintaining the status quo is unrealistic.However, the new ASCO policy position 1 to increase participation in 340B is not reform.Expanding institutional access to 340B revenue streams without restructuring incentives should not be mistaken for meaningful change.The goal should be rebuilding 340B around patients, accountability, transparency, and lower cost care delivery-and ensuring that vulnerable Americans, not hospitals, receive the discounts.This concern also extends to allowing multiple contract pharmacy arrangements.Contract pharmacies in 340B have expanded dramatically and increasingly involve pharmacy benefit managers who do not directly deliver patient care. 2 Oversight remains another major challenge.The Government Accountability Office has repeatedly identified weaknesses involving contract pharmacy oversight, duplicate discounts, and compliance monitoring.3 Expanding participation while assuming the current oversight infrastructure can adequately manage a larger and more complex program risks creating even greater opacity.
Autor:innen und Institutionen
- Ted Okon, MBA, and Nicolas Ferreyros, BA, Community Oncology Alliance, Washington, DC.
ORCID-Profile: Ted Okon, Nicolas Ferreyros
Zitieren
APA
Okon, T., & Ferreyros, N. (2026). Participation Is Not Reform: Why 340B Discounts Should Follow the Patient. JCO Oncology Practice. https://doi.org/10.1200/op-26-00620
Vancouver
Okon T, Ferreyros N. Participation Is Not Reform: Why 340B Discounts Should Follow the Patient. JCO Oncology Practice. 2026. doi:10.1200/op-26-00620
BibTeX
@article{Okon2026,
author = {Okon, Ted and Ferreyros, Nicolas},
title = {Participation Is Not Reform: Why 340B Discounts Should Follow the Patient},
journal = {JCO Oncology Practice},
year = {2026},
doi = {10.1200/op-26-00620}
}
EUVIMED